OUR STORY

David founded Molekule Consulting with an ethos of strategic and actionable competitive insight combined with client centricity. He is responsible for numerous engagements with varied scopes and objectives in the competitive intelligence and primary market research areas. Project scopes range from pre-clinical through launch and lifecycle management (“LCM”) to supporting clients in clinical and commercial strategy development.

His major therapy expertise is in oncology, ophthalmology, cardiovascular, diabetes, autoimmune, and CNS. David attends numerous major medical congresses and scientific congresses globally.

Michael is a uniquely experienced competitive intelligence (CI) professional and therapeutic area expert, who joined Molekule in 2017, where he has since led high-impact engagements across domains. Stylistically, he brings first-hand experience, rigorous attention to delivery, and lateral thinking to the management team and client engagements.

Mike began his career in Neuroscience Drug Discovery at Merck Research Labs. Following a PhD in the same field, completed at the University of Amsterdam and National Institutes of Health, he joined Deallus Consulting and was subsequently recruited to Occam Global, prior to joining Molekule.

Dr. Mark Powzaniuk joined Molekule Consulting after spending 19 years within the pharmaceutical industry. As a seasoned pharmaceutical professional, he brings a unique background of science and business acumen. His experiences include Basic Research, Project Management, and Finance. Most recently, Mark was head of Global Competitive Intelligence, Oncology at Merck.

Mark started his career as a Post-Doctoral Research Fellow in the Bone Biology Department at Merck. After completing his fellowship, he joined Merck Project Management with increasing roles of responsibility, gaining both clinical and commercial experience. While obtaining his M.B.A., Mark transitioned to Business Integration and Finance. After a successful finance career, Mark joined Competitive Intelligence at Merck.

Oleh is a skilled competitive and business intelligence professional and a leader with an integrated background in biopharmaceuticals and healthcare. Having played key roles on the client side, he brings a keen knowledge of market and competitive intelligence expected by his clients and their internal partners including senior management. He is responsible for numerous engagements with varied scopes and objectives and assists in leading Strategic Competitive Simulation Workshops for clients. Oleh maintains his pharmacist license in two jurisdictions.

He practiced in hospital, long-term care and retail settings as the Pharmacist In Charge and was invited to join the Rho Chi Pharmacy Honor Society. He brings a holistic approach, using the 5-Forces Model, in obtaining actionable HUMINT (Human Intelligence) to help his clients make key decisions. Oleh is multilingual and attends numerous medical and scientific congresses globally.

Jayant is a CI expert adept in generating market and competitor insights. He joined Molekule in 2016 after significant blue chip pharma experience. At Novartis, Jayant delivered insights to global and country brand teams across the globe in support of multiple blockbuster brands. At Abbott, Jayant supported the leadership team in diverse projects related to SFE, CRM, and business analytics to achieve strategic objectives profitably and sustainably.

At Lilly, Jayant developed market research expertise in support of the Diabetes brand team. By academic training, Jayant is a biotechnology engineer and holds an MBA from the Indian Institute of Foreign Trade (IIFT).

Phil has a breadth of experience in the fundamental and practical applications of drug development and business strategy. Formally trained in biophysics and biochemistry, Phil has a keen understanding of the biopharma industry including preclinical and early development, new product planning, intellectual property and M&A due diligence, and commercialization from launch through life-cycle management.

Phil holds a Ph.D. in Pharmacology from the Yale School of Medicine, where he received an Excellence in Science Award from the American Academy for the Advancement of Science (AAAS). He received his undergraduate education in Molecular, Cellular and Developmental Biology from the University of Colorado, Boulder, and was an Amgen Scholar at the University of California, San Diego.

Drew joined Molekule Consulting after spending 19 years within the pharmaceutical industry. He has a unique breadth of knowledge spanning science, manufacturing, and strategic marketing. He provides insightful market intelligence, product evaluations, and strategic recommendations based on past experiences in portfolio management. Prior to Molekule Drew held progressive roles at Mallinckrodt Pharmaceuticals / Covidien in Strategic Marketing and R&D.

Drew started his career in R&D at Covidien, Pfizer (King), and the U.S. FDA. After completing his M.B.A., he transitioned to Strategic Marketing and was responsible for pipeline product sections, product management, commercial launches, and evaluation of BD&L opportunities as the lead of generic portfolio competitive intelligence.

Dr. Paul De Santis, PharmD joined Molekule Consulting after spending 4 years as a GLG special council member in Immuno-Oncology and Cell Therapy consulting for several of the largest global Private Equity and Hedge Funds with more than $10B in assets under management. During this time clients leveraged his depth of expertise on commercial dynamics operating within the Cell and Gene Therapy landscape to perform deep-dive addressable market analyses and leveraged his clinical expertise to understand an assets probability of regulatory and commercial success in support of valuation analysis.

In addition, he supported pre-commercial planning for several CAR T companies leveraging these skillsets to develop commercialization strategies that can maximize patient access to autologous cell therapies. Dr. De Santis provides deep expertise across the hematology/oncology and immuno-oncology landscapes and this is supported by 4 years of clinical training and 5 years of translational oncology research.

Dr. Neha Dalmia joined Molekule with >13 years of scientific and business experience, having a unique ability to synthesize complex datasets into actionable insights. She has >5 years of market research, business strategy, and competitive intelligence (CI) experience in diverse therapeutic areas including immunology, oncology, biosimilars, and CNS. 

She also brings significant experience regarding innovation for in vitro diagnostics, social media monitoring, and mentorship, having supported more than 60 startups in the medical devices and digital health field as part of the MedTech Innovator Accelerator, and having previously led development of PulseTraQ, within TheratraQ, building two service-based offerings for research on various social media platforms.

Michael started at Molekule in April 2022, and brings broad therapeutic experience from a prior role as a Senior Consultant at Kantar Health, where he built forecast models for pharma clients, conducted primary and secondary research, competitive intelligence.

Prior to joining Molekule, Michael was the Director of Forecasting, BD&L / Portfolio at Mallinckrodt Pharmaceutical’s Specialty Generics business. 

There, Michael’s role was a strategic one, suggesting and vetting product ideas for addition to Mallinckrodt’s generics pipeline, taking into account factors including IP protection and ANDA filers, generic price erosion and order of entry modeling, and utilization of products within the treatment landscape when projecting company NPV-adjusted net revenue. Opportunities were both organic and inorganic, including analysis of many 3rd party business development commercial ventures.

Richa is a dedicated pharmaceutical professional with a strong scientific background and strategic business acumen. She brings notable experience of more than 16 years from a career in Competitive Intelligence, Business Research and Consulting supporting many leading US and European Pharmaceutical and Biotech Companies in various roles such as Key Account Management, Knowledge Management, Business Development, Primary and Secondary Research, Personnel Training, SME and Customer Insights.

Her background in Microbiology and Biotechnology with a rich experience in CI and Market Research has shaped Richa into a well-rounded domain expert with strong understanding of development and current trends mainly in the area of Oncology, Infectious Diseases and Vaccines.

A biophysicist by training, Dr. Brett Alcott is uniquely positioned as a biopharma industry subject matter expert and brings with him a deep appreciation for the importance of basic research in understanding disease mechanisms and improving human health. Brett’s academic research focused on the protein-lipid interplay underlying the fusion of membrane-enveloped viruses, such as influenza, Ebola and HIV, with their host cells. His work sought to isolate and characterize the fusion pore – a transient lipidic connection between virus and host and a crucial early intermediate in the infection process – using an experimental approach which combined a novel, nanoscale in vitro electrical technique (capable of inferring pore size with millisecond resolution) and radically coarse-grained molecular dynamics simulations.

Additionally, Brett developed a novel, robust single-cell fluorescence technique to report membrane fusion between cells expressing viral fusion proteins and bilayer nanodiscs of controllable size and chemical composition which could serve as a platform for future antiviral drug screens. A lifelong New Yorker, Brett holds a B.A. in Chemistry and Biochemistry from Cornell University, where he was a Cornell Presidential Research Scholar, and a Ph.D. in Biophysics from Columbia University (2017), where he was an NIH predoctoral fellow in Molecular Biophysics and an Exchange Scholar at Yale University.

Sid started his career as a molecular biologist in the Translational Medicine Lab at ACTREC (India’s foremost cancer research hospital) where the team was trying to identify novel mechanisms for metastasis and ways to prevent it. However, he soon realized that a narrow focus - on a single target/ pathway is not enough and decided to move into consulting to get a more holistic/ bird’s eye view of things.

His background in Oncology due to his M.Sc. in Cancer immunology and strong understanding of the mechanics behind the various molecular pathways due to his research experience provided the base required to integrate with the commercial side. His education and experience in CI and market research have molded Sid into a well-rounded therapy area expert with a strong understanding of the developments and current trends in oncology.

Having her roots in India, Priyanka has about 9 years of experience in strategic consulting and market research, primarily in the pharma and healthcare industry. She has spent numerous years leading engagements spanning competitive and marketing intelligence, commercial strategy, launch plan, lifecycle management, indication prioritization, pipeline/ landscape analysis, competitor wargaming, and market opportunity assessment.

She holds a Master’s degree in Biotechnology. Her major therapy expertise is in rare diseases, CNS, and metabolic disorders. She feels passionate about competitive intelligence to reinforce her clients’ success throughout the lifecycle of a product.

Sharon Rosaler began her career as an accountant at Ernst & Young before entering the private sector. Prior to her appointment to CFO, Sharon headed Molekule’s accounting department since 2016. Sharon’s deep background in healthcare accounting is underpinned by the development of financial relationships, raising capital, satisfying financial obligations, ensuring record control, merger and acquisitions, strategy, and due diligence evaluation. She holds a Bachelor’s Degree in Business Administration and a Masters of Accounting Degree from the University of Miami from 2004